- Consumer Products
- Latest 65.14
- Currency US$
- Change 2.26
- Percent Change 3.594 %
- Volume 1,241,459
- Fri Dec 20, 2013 04:00 PM EST NASDAQ data delayed 15 minutes.
12 months ended Sep 30, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||Nov 12||$-0.28||Feb 27||$-0.14|
12 months ended Dec 21, 2013.
A look at major corporate events and financial announcements that are coming up.
About the Company
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. The Company had built a portfolio of innovative medical technologies and a team of employees and seasoned consultants with significant expertise in the identification, evaluation, acquisition, development and sale/partnering of small molecule therapeutics, biotechnology products and medical devices